Artificial coma/medically induced coma Market to be driven by Increase in traumatic brain injury prevalence and an increase in government and private funding for the expansion of the healthcare industries

Market Highlights

The global artificial coma/medically induced coma market is accounted to register a CAGR of 3.50% during the forecast period and is estimated to reach USD 1.09 billion by 2032.

An increase in surgical procedures like cosmetic surgery and brain surgery results in using medications like propofol and barbiturates to put patients into a coma. Additionally, a rising senior population substantially contributes to the market's expansion. The growth in the manufacture of various coma-inducing medications is a major factor propelling the global market. Contrarily, it is projected that danger connected with pregnant women and adverse effects related to artificial coma/medically produced coma may restrain market expansion over the projection period. Key competitors in the artificial coma/medically induced coma market are expected to benefit from large growth potential due to emerging markets, major R&D to discover effective medications and unmet demand in underdeveloped and developing nations.

Key Players

The following businesses are considered the significant players by MRFR for global artificial coma/medically induced coma market— Piramal Group, Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals, Fresenius Se & Co Kgaa, Astrazeneca Plc, Dr. Reddy’s Laboratory, Pfizer Inc., Viatris Inc. (Mylan N.V), B.Braun Melsungen Ag, Baxter International Inc.

Segment Analysis

The global artificial coma/medically induced coma market has been segmented based type, application, and distribution channel.

Based on type, the market is segmented into propofol and barbiturate. The propofol segment was attributed to holding the largest market share in 2022. This is important since many people do not remember or are unaware of the warning signs and symptoms of stroke. Propofol is a well-liked anesthetic employed for various surgical procedures, including general anesthesia, sedation, and procedural sedation.

Based on application, the global artificial coma/medically induced coma market has been segmented into status epilepticus, stroke, traumatic brain injury, brain infections, drug overdose, and others. The stroke segment was expected to hold the largest market share in 2022. This is important since many people do not remember or are unaware of the stroke warning signs and symptoms.

Based on distribution channels, the global artificial coma/medically induced coma market has been segmented into hospital pharmacies, drug stores & retail pharmacies. The hospital pharmacies segment was expected to hold the largest market share in 2022. The aging of the population, the rise in chronic illnesses, the frequency of lifestyle disorders, and the number of stroke victims with diabetes are all factors that will lead to the market's growth.

Regional Analysis

The global artificial coma/medically induced coma market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe artificial coma/medically induced coma market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The artificial coma/medically induced coma market in Asia-Pacific has been segmented into China, South Korea, India, Japan, Australia,  , and the rest of Asia-Pacific. The Rest of the World artificial coma/medically induced coma market comprises of Middle East, Africa, and Latin America.

The largest market share for artificial coma/medically induced coma was maintained by the North American regional sector. The elderly are increasingly prone to suffer from medical diseases that call for a medically induced coma, such as stroke, traumatic brain injury, and status epilepticus, as the population of North America ages. Also, chronic illnesses like cancer and heart disease are becoming more common in North America. These illnesses can occasionally result in side effects including brain swelling or seizures that call for a medically induced coma.

Moreover, the Europe market has been persistently growing over the forecast period. Longer-term medically induced comas may now be safely induced and maintained because to developments in medical technology like ventilators and brain monitoring. This has made a larger range of individuals and illnesses eligible to use medically induced coma.

Additionally, in Asia Pacific, road accidents are the main cause of fatalities and disabilities. Governments in the Asia Pacific region are expanding their investments in healthcare as a result of the high rate of accidents that cause traumatic brain injury, which might occasionally necessitate a medically induced coma. As a result, there is now more money available to treat people who need to be put into a coma by medicine.

Furthermore, the rest of the world's artificial coma/medically induced coma market is divided into the Middle East, Africa, and Latin America. This growth is attributed to the region's owing to increase in stroke patients.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Artificial Coma/Medically Induced Coma Market Research Report

Key Findings of the Study

• The global artificial coma/medically induced coma market is expected to reach USD 1.09 billion by 2032, at a CAGR of 3.50% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market due to the rising increasing investments in healthcare


• Based on end user, the hospital pharmacies segment was attributed to holding the largest market in 2022, with an approximate market share of 55-74%.


• Piramal Group, Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals, Fresenius Se & Co Kgaa, Astrazeneca Plc, Dr. Reddy’s Laboratory, Pfizer Inc., Viatris Inc. (Mylan N.V), B.Braun Melsungen Ag, Baxter International Inc.